1. Recent trends in the therapy of urinary tract infections

   • H. Bucht

   Introduction Pages: S309 - S312

2. Synergistic antibacterial activity in vitro of trimethoprim and sulphonamides and the importance of pharmacokinetic properties for optimal therapy

   • J. K. Seydel
   • E. Wempe

   Bacteriological Evaluation Pages: S313 - S320

3. The effect of trimethoprim-sulphonamide, trimethoprim and sulphonamide on the occurrence of resistant enterobacteriaceae in human intestinal flora

   • H. Knothe

   Bacteriological Evaluation Pages: S321 - S323

4. Synergistic activity of co-trimazine and co-trimoxazole in the urine

   • J. Acar
   • B. Ekström
   • B. Huitfeldt

   Bacteriological Evaluation Pages: S324 - S329

5. The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues

   • D. S. Reeves
   • P. J. Wilkinson

   Pharmacological Evaluation Pages: S330 - S341

6. Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat

   • W. Ritzerfeld

   Pharmacological Evaluation Pages: S342 - S344

7. Co-trimazine distribution in the canine prostate

   • N. Frimodt-Möller
   • S. Maigaard
   • K. G. Naber

   Pharmacological Evaluation Pages: S345 - S348

8. Renal lymph and interstitial fluid concentration of co-trimazine: An experimental study in dogs

   • S. Maigaard
   • N. Frimodt-Möller
   • P. O. Madsen

   Pharmacological Evaluation Pages: S349 - S353

9. Studies on the optimal dosage of co-trimazine in children

   • P. G. Bergfors

   Pharmacological Evaluation Pages: S354 - S358

10. Development of sulphonamide-trimethoprim combinations for urinary tract infections

    • B. Ekström
    • U. Forsgren
    • T. Bergan

    Pharmacological Evaluation Pages: S359 - S366

11. Development of sulphonamide-trimethoprim combinations for urinary tract infections

    • B. Örtengren
    • H. Fellner
    • T. Bergan

    Pharmacological Evaluation Pages: S367 - S370

12. Development of sulphonamide-trimethoprim combinations for urinary tract infections

    • B. Örtengren
    • L. Magni
    • T. Bergan

    Pharmacological Evaluation Pages: S371 - S381

13. Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function

    • T. Bergan
    • E. K. Brodwall
    • U. Ånstad

    Pharmacological Evaluation Pages: S382 - S387

14. General survey of trimethoprim combinations in the treatment of urinary tract infections

    • W. Brumfitt
    • J. M. T. Hamilton-Miller

    Clinical Evaluation Pages: S388 - S393

15. Comparison of long- and short-term treatment of recurrent urinary tract infection

    • W. Marget
    • B. H. Belohradsky
    • B. Nickel

    Clinical Evaluation Pages: S394 - S397

16. Double-blind comparison of sulphonamide-trimethoprim combinations in acute uncomplicated urinary tract infections

    • O. Skjerven
    • T. Bergan

    Clinical Evaluation Pages: S398 - S400

17. A clinical study of co-trimazine in comparison with co-trimoxazole and sulphalene in urinary tract infections

    • A. Lövestad
    • B. Gästrin
    • R. Lundström

    Clinical Evaluation Pages: S401 - S403

18. The use of co-trimazine and co-trimoxazole in elderly patients with urinary tract infections

    • S. Allgulander
    • S. Holm
    • C. Lundgren

    Clinical Evaluation Pages: S404 - S407

19. Clinical studies on co-trimazine in children

    • P. G. Bergfors

    Clinical Evaluation Pages: S408 - S410

20. Clinical study of co-trimazine in urinary tract infections: A comparison with nitrofurantoin

    • J. Belsheim
    • H. Gnarpe
    • A. Svensson

    Clinical Evaluation Pages: S411 - S413

21. Treatment of urinary tract infections with sulphonamide and/or trimethoprim

    • C. E. Mabeck
    • R. Vejlsgaard

    Clinical Evaluation Pages: S414 - S416

22. Trimethoprim/sulphonamide: Concluding remarks

    • W. Marget

    Clinical Evaluation Pages: S417 - S418

23. Impressum

    Legacy Pages: S420 - S420